Alto Neuroscience (Alto Neuroscience) Preferred Dividends : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Alto Neuroscience Preferred Dividends?

Preferred dividend is a dividend that is accrued and paid on a company's preferred shares. Alto Neuroscience's preferred dividends for the three months ended in Mar. 2024 was $0.00 Mil. Its preferred dividends for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Alto Neuroscience Preferred Dividends Historical Data

The historical data trend for Alto Neuroscience's Preferred Dividends can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alto Neuroscience Preferred Dividends Chart

Alto Neuroscience Annual Data

Trend

Dec21

Dec22

Dec23

Preferred Dividends

Alto Neuroscience Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Sep23	Dec23	Mar24
Preferred Dividends	Get a 7-Day Free Trial			-	-	-	-	-

Alto Neuroscience Preferred Dividends Calculation

A dividend that is accrued and paid on a company's preferred shares.

Alto Neuroscience (NYSE:ANRO) Preferred Dividends Explanation

In the event that a company is unable to pay all dividends, claims to preferred dividends take precedence over claims to dividends that are paid on common shares.

Preferred Dividends for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Alto Neuroscience (Alto Neuroscience) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alto Neuroscience Inc (NYSE:ANRO) » Definitions » Preferred Dividends

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

Alto Neuroscience Inc is a clinical stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and highly effective treatment options. the company currently consists of five clinical-stage assets initially targeting major depressive disorder and schizophrenia populations as identified by independent brain-based biomarkers.

Alto Neuroscience (Alto Neuroscience) Headlines

From GuruFocus

Steven Cohen's Point72 Asset Management Buys New Stake in Alto Neuroscience Inc

By GuruFocus Research • 02-08-2024